Free Trial

Cassava Sciences (NASDAQ:SAVA) Stock Price Up 5.7%

Cassava Sciences, Inc. (NASDAQ:SAVA - Get Free Report)'s share price was up 5.7% during mid-day trading on Monday . The company traded as high as $22.58 and last traded at $22.52. Approximately 215,274 shares were traded during trading, a decline of 68% from the average daily volume of 666,202 shares. The stock had previously closed at $21.31.

Analyst Ratings Changes

Separately, HC Wainwright restated a "buy" rating and set a $124.00 price target on shares of Cassava Sciences in a report on Tuesday, March 5th.

Check Out Our Latest Report on SAVA

Cassava Sciences Stock Performance

The stock has a market capitalization of $1.02 billion, a P/E ratio of -9.99 and a beta of -0.45. The business has a fifty day simple moving average of $22.08 and a 200-day simple moving average of $19.13.

Cassava Sciences (NASDAQ:SAVA - Get Free Report) last issued its earnings results on Wednesday, February 28th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.10). On average, sell-side analysts anticipate that Cassava Sciences, Inc. will post -2.01 earnings per share for the current year.


Hedge Funds Weigh In On Cassava Sciences

A number of large investors have recently modified their holdings of the company. BlackRock Inc. lifted its holdings in shares of Cassava Sciences by 4.7% in the 2nd quarter. BlackRock Inc. now owns 2,746,908 shares of the company's stock worth $67,354,000 after purchasing an additional 124,231 shares in the last quarter. Vanguard Group Inc. raised its position in Cassava Sciences by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 2,324,626 shares of the company's stock valued at $52,327,000 after buying an additional 56,060 shares during the last quarter. State Street Corp raised its position in Cassava Sciences by 6.5% in the 1st quarter. State Street Corp now owns 1,058,949 shares of the company's stock valued at $25,542,000 after buying an additional 64,903 shares during the last quarter. Geode Capital Management LLC raised its position in Cassava Sciences by 5.8% in the 2nd quarter. Geode Capital Management LLC now owns 803,306 shares of the company's stock valued at $19,697,000 after buying an additional 44,350 shares during the last quarter. Finally, Gallacher Capital Management LLC raised its position in Cassava Sciences by 0.7% in the 4th quarter. Gallacher Capital Management LLC now owns 581,606 shares of the company's stock valued at $13,092,000 after buying an additional 3,782 shares during the last quarter. 38.05% of the stock is currently owned by institutional investors.

Cassava Sciences Company Profile

(Get Free Report)

Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.

Featured Stories

Should you invest $1,000 in Cassava Sciences right now?

Before you consider Cassava Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cassava Sciences wasn't on the list.

While Cassava Sciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Featured Articles and Offers

Search Headlines: